---
title: "Sarepta Therapeutics, Inc.亏损警报：提醒有亏损的投资者注意 8 月 25 日集体诉讼的截止日期，请联系 BFA Law（NASDAQ:SRPT）"
description: "纽约，2025 年 8 月 17 日（GLOBE NEWSWIRE）-- 领先的证券法律事务所 Bleichmar Fonti & Auld LLP 宣布，已对 Sarepta Therapeutics, Inc.（SRPT）及该公司某些高级管理人员提起诉讼，指控其可能违反联邦证券法"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/253350398.md"
published_at: "2025-08-17T12:06:24.000Z"
---

# Sarepta Therapeutics, Inc.亏损警报：提醒有亏损的投资者注意 8 月 25 日集体诉讼的截止日期，请联系 BFA Law（NASDAQ:SRPT）

> 纽约，2025 年 8 月 17 日（GLOBE NEWSWIRE）-- 领先的证券法律事务所 Bleichmar Fonti & Auld LLP 宣布，已对 Sarepta Therapeutics, Inc.（SRPT）及该公司某些高级管理人员提起诉讼，指控其可能违反联邦证券法

NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.

### Related Stocks

- [SRPT.US - Sarepta医疗](https://longbridge.com/zh-CN/quote/SRPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Sarepta rises on NZ regulatory nod to start Huntington's disease trial | Sarepta Therapeuticsshares rose 3% to $20.92 in premarket trading after receiving regulatory approval in New Zealand to  | [Link](https://longbridge.com/zh-CN/news/274824082.md) |
| Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics | During the last three months, 8 analysts evaluated Sarepta Therapeutics (NASDAQ:SRPT), showing a range of bullish to bea | [Link](https://longbridge.com/zh-CN/news/272548848.md) |
| Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics | Needham analyst Gil Blum has reiterated a Sell rating on Sarepta Therapeutics (SRPT) due to concerns over its growth out | [Link](https://longbridge.com/zh-CN/news/272438221.md) |
| Sarepta Therapeutic Q4 prelim net product revenue misses estimates | Sarepta Therapeutics reported preliminary Q4 net product revenue of $369.6 million, missing analyst estimates of $382.07 | [Link](https://longbridge.com/zh-CN/news/272301526.md) |
| JPM26: Sarepta CEO touts “avalanche of Elevidys data” amid 2025 safety woes | Sarepta's CEO Douglas Ingram presented at the J.P. Morgan Healthcare Conference, discussing the challenges faced by Elev | [Link](https://longbridge.com/zh-CN/news/272413649.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。